Inflammatory and infectious diseases have a high prevalence, morbidity, and mortality worldwide. Despite the existence of a considerable number of drugs for the management of these diseases, there are several conditions in which they are not effective or have side effects that limit their use. In the context of chronic inflammatory diseases, the prolonged use of anti-inflammatory drugs, especially corticosteroids and non-steroidal anti-inflammatory drugs, is accompanied by significant toxicity. In the context of infectious diseases, there are at least two major challenges:
A) Few therapeutic options for the treatment of neglected diseases such as malaria, leishmaniasis, and trypanosomiasis, urgently demanding the development of novel, safer, and more effective pharmaceutical formulations;
B) The rapid emergence of multi-drug resistant microorganisms has limited the effectiveness of virtually all classes of antimicrobials, especially antibacterial and antifungal drugs, which are also not free from significant toxicity. In this context, natural products, especially medicinal plant-derived secondary metabolites, represent important sources of new chemical entities with the potential to be used in drug development, especially in the context of inflammatory and infectious diseases.
This is the second volume of the Research Topic series and aims to further gather manuscripts with active pharmacological principles of the extracts presenting fully characterized and quantified natural products demonstrating effectiveness against inflammatory and infectious diseases in the context of preclinical research. This collection aims to develop the original findings as well as identify new research within the area.
We encourage submissions of all article types demonstrating the pharmacological effects and mechanism of action of natural products through, but not limited to the following topics:
-Animal and in vitro models of inflammation, allergy, and pain
-Investigation of new antibacterial and antifungal compounds
-Development of new anti-parasitic drugs
-Pre-clinical research on neglected tropical diseases
-Experimental modulation of antimicrobial resistance
Inflammatory and infectious diseases have a high prevalence, morbidity, and mortality worldwide. Despite the existence of a considerable number of drugs for the management of these diseases, there are several conditions in which they are not effective or have side effects that limit their use. In the context of chronic inflammatory diseases, the prolonged use of anti-inflammatory drugs, especially corticosteroids and non-steroidal anti-inflammatory drugs, is accompanied by significant toxicity. In the context of infectious diseases, there are at least two major challenges:
A) Few therapeutic options for the treatment of neglected diseases such as malaria, leishmaniasis, and trypanosomiasis, urgently demanding the development of novel, safer, and more effective pharmaceutical formulations;
B) The rapid emergence of multi-drug resistant microorganisms has limited the effectiveness of virtually all classes of antimicrobials, especially antibacterial and antifungal drugs, which are also not free from significant toxicity. In this context, natural products, especially medicinal plant-derived secondary metabolites, represent important sources of new chemical entities with the potential to be used in drug development, especially in the context of inflammatory and infectious diseases.
This is the second volume of the Research Topic series and aims to further gather manuscripts with active pharmacological principles of the extracts presenting fully characterized and quantified natural products demonstrating effectiveness against inflammatory and infectious diseases in the context of preclinical research. This collection aims to develop the original findings as well as identify new research within the area.
We encourage submissions of all article types demonstrating the pharmacological effects and mechanism of action of natural products through, but not limited to the following topics:
-Animal and in vitro models of inflammation, allergy, and pain
-Investigation of new antibacterial and antifungal compounds
-Development of new anti-parasitic drugs
-Pre-clinical research on neglected tropical diseases
-Experimental modulation of antimicrobial resistance
